$TLPH News

HC Wainwright & Co. Assumes Talphera at Buy, Announces Price Target of $3

Talphera, Inc. Q1 2026 Earnings Call Summary

Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...

Talphera Q1 2026 Earnings Call Transcript

Talphera (TLPH) Q1 2026 Earnings Transcript

Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update

Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript

Talphera Q1 2026 Earnings Call Transcript

Talphera Q1 EPS $(0.04) Beats $(0.07) Estimate, Sales $0.00 Down From $27.000K YoY

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026

WestPark Capital Initiates Coverage On Talphera with Buy Rating, Announces Price Target of $3

Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026

Talphera, Inc. (TLPH) Analyst/Investor Day Transcript

Talphera: Q4 Earnings Snapshot

Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Talphera Q4 EPS $(0.06) Beats $(0.14) Estimate

Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026

Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial

Talphera Announces 50% Patient Enrollment Of NEPHRO-CRRT Clinical Trial

This Talphera Insider Increased Their Holding By 138% Last Year